Sanofi & United States
9 shared events · Importance 3 · Last updated Apr 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Regulatory
Sanofi: Sanofi faced safety questions from Tracy Beth Høeg regarding its RSV treatments and was prompted to remove its Type 1 diabetes drug, teplizumab, from a pilot program due to disagreements with United States — Food and Drug Administration scientists.
United States: The United States' health policy and regulatory landscape are being reshaped by the ongoing personnel changes and political influence within its government agencies, particularly concerning vaccine policies.
May 15, 2026 · 6 articles
Business
Sanofi: Sanofi, in collaboration with Regeneron Pharmaceuticals, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
Domestic
Sanofi: Sanofi is a major insulin maker that has moved to cut the cost of insulin and offers a savings program for people without health insurance.
Apr 02, 2026 · 6 articles
Domestic
Sanofi: Sanofi, a hepatitis B vaccine maker, defended its products as safe, and its U.S.-listed shares ended up 1.3%.
Dec 05, 2025 · 7 articles
Regulatory
Sanofi: Sanofi is mentioned as a collaborator with Innate Pharma in immuno-oncology.
Apr 02, 2026 · 7 articles
Regulatory
Sanofi: Sanofi is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations.
Apr 13, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how Sanofi and United States interact across events, view sentiment trends, and discover connected entities.
Open Dashboard